Filing Flows › Lemaitre Vascular (LMAT) › Q3 2025
Lemaitre Vascular (LMAT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 7, 2025
Lemaitre Vascular (LMAT) reported revenue of $61.0M for the third quarter 2025 (Q3 2025), +11% from a year earlier and -5% from the quarter before. Operating margin was 33.3%, net earnings $17.4M (28.4% of revenue).
Lemaitre Vascular, Q3 2025: revenue $61.0M (+11% year over year), operating margin 33.3%, net earnings $17.4M, operating cash flow $28.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $61.0M | -5% | +11% |
| Gross profit | $46.0M | +2% | +24% |
| Operating profit | $20.3M | +26% | +54% |
| Net earnings | $17.4M | +26% | +56% |
| Operating cash flow | $28.8M | +42% | +102% |
| Free cash flow | $26.5M | +40% | +111% |
What changed
Revenue was $61.0M in Q3 2025, up 11% year over year and down 5% from the previous quarter.
Gross margin was 75.3%, up 7.5 points from a year earlier. Operating profit was $20.3M, a 33.3% margin (up 9.3 points year over year). Of the extra revenue versus a year earlier, 115% reached operating profit, above the 24% margin then. Operating expenses grew 7% against revenue growth of 11%. The fastest-growing cost line was General & admin (+20%). Net earnings were $17.4M, up 56% year over year. The effective tax rate was 23.1%.
Operating cash flow was $28.8M (up 102% year over year), 166% of net earnings. Non-cash charges added back $2.6M of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items added $7.0M. Capital expenditures of $2.3M left free cash flow of $26.5M.
Questions
What was Lemaitre Vascular's revenue in the third quarter 2025?
Lemaitre Vascular (LMAT) reported revenue of $61.0M for the third quarter 2025 (Q3 2025), +11% from a year earlier and -5% from the quarter before.
Was Lemaitre Vascular profitable in the third quarter 2025?
Operating profit was $20.3M (33.3% of revenue) and net earnings $17.4M.
Source: Lemaitre Vascular 10-Q on SEC EDGAR.